Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: A new approach to risk factor management

Drugs

Volumn 68, Issue 7, 2008, Pages 885-900

  Mason, R Preston ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

^c Cummings Center   (United States)

Author keywords

Amlodipine, therapeutic use; Atorvastatin, therapeutic use; Cardiovascular disorders

Indexed keywords

AMLODIPINE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PRAVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DYSLIPIDEMIA; HEADACHE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; MYALGIA; NOTE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; RESPIRATORY TRACT INFECTION; RISK FACTOR; VASCULAR ENDOTHELIUM;

AMLODIPINE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; RISK FACTORS;

EID: 43249095724     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868070-00001     Document Type: Note

References (88)

1. Yach D, Hawkes C, Gould CL, et al. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004; 291 (21): 2616-22
2. Flack JM, Casciano R, Casciano J, et al. Cardiovascular disease costs associated with uncontrolled hypertension. Manag Care Interface 2002; 15 (11): 28-36
3. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care 2002; 25 (3): 482-6
4. Beaglehole R, editor. The world health report: 2003. Shaping the future. Geneva: WHO, 2003
5. Murray CJL, Lopez AD. The global burden of disease. Boston (MA): Harvard School of Public Health, 1996
6. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303 (6797): 276-82
7. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet 2005; 365 (9457): 434-41
8. Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992; 86 (3): 1046-60
9. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16 (2): 434-44
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
11. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363 (9411): 757-67
12. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110 (2): 227-39
13. Williams B, Wilson K, Lacey L, et al. The prevalence and management of patients with co-existing hypertension and hypercholesterolaemia in the UK. European Society of Cardivascular ology 2004 congress; 2004 Aug 28-Sep 1; Munich
14. Johnson ML, Pietz K, Battleman DS, et al. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care 2004; 10 (12): 926-32
15. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss 2004; 97 (10): 1019-30
16. European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-53
17. NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143-421
18. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25 (6): 484-91
19. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2): 293-8
20. The University of Edinburgh. Cardiovascular risk calculator [online]. Available from URL: http://cvrisk.mvm.ed.ac.uk/calculator/framingham.htm [Accessed 2008 Mar 25]
21. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109 (23 Suppl. 1): III27-32
22. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997; 20 (11 Suppl. 2): II-3-10
23. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81 (2): 491-7
24. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23 (2): 233-46
25. Mason RP. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med 2005; 118 Suppl. 12A: 54-61
26. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105 (17): 2107-11
27. Vergnani L, Hatrik S, Ricci F, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation 2000; 101 (11): 1261-6
28. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-61
29. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109 (21 Suppl. 1): II34-41
30. Quyyumi AA, Mulcahy D, Andrews NP, et al. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia: comparison of acetylcholine and substance P. Circulation 1997; 95 (1): 104-10
31. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 2003; 23 (12): 2155-63
32. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97 (6): 576-80
33. Zhang X, Kichuk MR, Mital S, et al. Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am J Cardiol 1999; 84 (4A): 27-33L
34. Mason RP, Campbell SF, Wang SD, et al. Comparison of location and binding for the positively charged 1,4-dihydro-pyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol 1989; 36 (4): 634-40
35. 2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol 1992; 41 (2): 315-21
36. Kuryata OV, Yegorova YV. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis. Kardiol Pol 2006; 64 (1): 44-8
37. Laufs U, Wassmann S, Hilgers S, et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001; 88 (11): 1306-7
38. Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000; 36 (5): 617-21
39. Mercuro G, Zoncu S, Saiu F, et al. Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels. Am J Cardiol 2002; 90 (7): 747-50
40. Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36 (2): 410-6
41. Tan KC, Chow WS, Tam SC, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87 (2): 563-8
42. Wassmann S, Ribaudo N, Faul A, et al. Effect of atorvastatin 80mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl. Am J Cardiol 2004; 93 (1): 84-8
43. Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric hyperoxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103 (1): 113-8
44. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108 (4): 426-31
45. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105 (6): 691-6
46. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107 (13): 1750-6
47. Manfrini O, Pizzi C, Morgagni G, et al. Effect of pravastatin on myocardial perfusion after percutaneous transluminal coronary angioplasty. Am J Cardiol 2004; 93 (11): 1391-430
48. Walter DH, Fichtlscherer S, Britten MB, et al. Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002; 89 (1): 1-6
49. Iwakura K, Ito H, Kawano S, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27 (5): 534-9
50. Beckman JA, Liao JK, Hurley S, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004; 95 (2): 217-23
51. Mason RP, Jacob RF, Kay RD, et al. Synergistic stimulation of nitric oxide release from human endothelial cells with amlodipine and atorvastatin [abstract]. Eur Heart J 2003; 24: 214A
52. van de Poll SW, Delsing DJ, Jukema JW, et al. Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002; 164 (1): 65-71
53. Delsing DJ, Jukema JW, van de Wiel MA, et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 2003; 42 (1): 63-70
54. Jeng JR, Sheu WH, Jeng CY, et al. Impaired fibrinolysis and insulin resistance in patients with hypertension. Am J Hypertens 1996; 9 (5): 484-90
55. Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79 (1): 84-7
56. Seljeflot I, Tonstad S, Hjermann I, et al. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002; 105 (4): 285-90
57. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 2005; 91 (1): 27-31
58. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004; 17 (9): 823-7
59. Cohn JN. Vascular wall function as a risk marker for cardiovascular disease. J Hypertens Suppl 1999; 17 (5): S41-4
60. Leibovitz E, Beniashvili M, Zimlichman R, et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperoxide lipidemic patients. Am J Hypertens 2003; 16 (9 Pt 1): 715-8
61. Cohn JN, Neutel J, Houston M, et al. Early improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia: the Avalon Arterial Wall Compliance (AWC) trial [abstract no. LB3]. American Society of Hypertension 20th Scientific Meeting; 2005 May 14-18; San Francisco (CA)
62. ALLHAT investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
63. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022-31
64. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study. A randomized controlled trial. JAMA 2004; 292 (18): 2217-25
65. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15): 1495-504
66. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685-96
67. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291 (9): 1071-80
68. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentions, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361 (9364): 1149-58
69. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 2001; 19 (6): 1139-47
70. Sever PS. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)? Am J Med 2005; 118 Suppl. 12A: 3-9
71. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27 (24): 2982-8
72. Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. Int J Clin Pract 2005; 59 (7): 839-46
73. Pedrinelli R, Esposti ED, Dell'Omo G. LDL cholesterol and global risk stratification in referred hypertensive patients. Atherosclerosis 2005; 180 (1): 137-43
74. Flack JM, Houston M, Neutel J, et al. Efficacy and safety of atorvastatin plus amlodipine versus either agent alone in patients with concomitant dyslipidaemia and hypertension: the AVALON study [abstract]. J Hypertens 2004; 22 Suppl. 1: 12S
75. Blank R, LaSalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens (Greenwich) 2005; 7 (5): 264-73
76. Dorval JF, Anderson T, Buithieu J, et al. Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. Am J Cardiol 2005; 95 (2): 249-53
77. Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J Clin Pharmacol 2007; 47 (12): 1555-69
78. Preston RA, Harvey P, Herfert O, et al. Reduction in Framingham cardiovascular risk with concomitant treatment of hypertension/dyslipidaemia with amlodipine/atorvastatin [poster]. Am J Hypertens 2005; 18 (5 Pt 2): 226-7A
79. Pfizer. Caduet® (amlodipine besylate/atorvastatin calcium) tablets: product information [online]. Available from URL: http://www.pfizer.com/files/ products/uspi_caduet.pdf [Accessed 2008 March 19]
80. Chung M, Randinitis E, Calcagni A, et al. Bioavailability of dual therapy: a fixed-dose combination tablet of amlodipine and atorvastatin [abstract]. XIIIth International Symposium on Atherosclerosis; 2003 Sep 28-Oct 2; Kyoto, 4
81. Pfizer. Amlodipine product information [online]. Available from URL: http://www.norvasc.com/professional [Accessed 2008 Mar 6]
82. Pfizer. Lipitor® (atorvastatin calcium) tablets [online]. Available from URL: http://www.pfizer.com/pfizer/download/uspi_lipitor.pdf. [Accessed 2008 Mar 6]
83. Chung M, Randinitis E, Calcagni A, et al. Effect of food on the bioavailability of dual therapy: a fixed-dose combination tablet of amlodipine and atorvastatin [abstract]. XIIIth International Symposium on Atherosclerosis; 2003 Sep 28-Oct 2; Kyoto, 174
84. Anon. Amlodipine/atorvastatin (Caduet) [letter]. Med Lett Drugs Ther 2004; 46 (1186): 56
85. Preston RA, Sun F, Tarasenko L. Safety and tolerability of coadministered amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidaemia in the Respond study [poster]. Am J Hypertens 2005; 18 (5 Pt II): 92-3A
86. Akosah KO, Gower E, Groon L, et al. Mild hypercholesterolemia and premature heart disease: do the national criteria underestimate disease risk? J Am Coll Cardiol 2000; 35 (5): 1178-84
87. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165 (10): 1147-52
88. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (9 Suppl.): 2-6